A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision

Olympus, a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, announced the plan to establish a series of Digital Excellence Centers (DECs) following acquisition of London-based Odin Vision, a cloud-AI endoscopy company with a strong portfolio of commercially available computer-aided detection/diagnostic solutions and innovation pipeline of cloud-enabled applications.

The acquisition has strengthened Olympus’ recently announced strategy and initiatives in digital health and brings the promise of AI-powered real-time diagnosis and minimally invasive treatment of chronic diseases closer to reality, ultimately raising the standard of care across multiple medical specialties and improving patient outcomes.

Envisioning an intelligent endoscopy ecosystem for the benefit of patients and healthcare providers

Odin Vision is contributing to Olympus’ vision of the future of endoscopy. Combining the strength of its core endoscopy portfolio with innovative digital solutions, Olympus plans to collect and analyze procedural, clinical and medical device data in real time, and then, powered by a new, modern digital platform leveraging the latest AI algorithms and software, provide healthcare professionals with clinical and operational solutions designed to reduce administrative and cognitive burdens while also improving operational efficiency. These advancements will support healthcare institutions as they endeavor to raise their level of care.

“As a leader in endoscopy and innovator in the space, Olympus is passionate about delivering the next generation of intelligent integrated solutions and insights to healthcare providers,” said Shawn LaRocco, Global VP Customer Solutions, responsible for the digital health business at Olympus. “However, we cannot do it alone and are continuously looking to partner with other pioneers like Odin Vision who share this passion.”

Digital Excellence Centers to push the envelope of creative innovation

To enable this commercial strategy, Olympus plans to develop and establish DECs for the development of digital solutions around the world, beginning in London where the acquisition of Odin Vision has laid the groundwork. In addition to its portfolio, Odin Vision brings renowned AI and software expertise and development capabilities that synergize and further accelerate Olympus’ digital health strategy. DECs are to be located at current Olympus R&D sites in Hamburg, Boston and Tokyo, with the possibility of expanding to Silicon Valley and Tel Aviv at a later stage.

Peter Mountney, Ph.D., CEO of Odin Vision commented, “We are excited to set the stage for future innovation development by leading Olympus’ plans for the first DECs, all in the pursuit of empowering clinicians to deliver the best possible care and outcomes to patients using the latest digital and AI tools.”

“As Olympus looks to expand development capabilities in digital solutions, establishing DECs around the globe will allow us to access critical talent and to develop partnerships with start-ups and other companies who, like Odin Vision, are pushing the envelope of creative innovation,” said Karsten Klose, Global Head of Digital at Olympus.

Olympus and Odin Vision at HIMSS23

Olympus and Odin Vision will be at HIMSS23 European Healthcare Conference & Exhibition, from June 7 to 9, in Lisbon, Portugal.

– On stage: Olympus and Odin Vision will be on stage from 11:00-11:50 on Friday, June 8, at the center stage in the Centro de Congressos de Lisboa. They will discuss how digital solutions like Odin Vision’s are being integrated into patient care, leading to better outcomes.
– In the exhibition: Olympus will be present at the congress on June 8 and 9 can be found in Booth 826.

SourceOlympus
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy